• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黏多糖贮积症 II 型患者的关节活动度受限:与身高、年龄和功能状态的相关性。

Restricted joint range of motion in patients with MPS II: correlation with height, age and functional status.

机构信息

Metabolic Diseases Clinic, The Children's Memorial Health Institute, Warsaw, Poland.

出版信息

Acta Paediatr. 2012 Apr;101(4):e183-8. doi: 10.1111/j.1651-2227.2011.02522.x. Epub 2011 Dec 1.

DOI:10.1111/j.1651-2227.2011.02522.x
PMID:22077147
Abstract

AIM

The aims of the study were to assess shoulder range of motion (ROM) in patients with mucopolysaccharidosis type II (MPS II) and to correlate joint mobility with patients' height, age and functional status.

METHODS

Passive ROM and Z-score of height were followed in 29 patients with MPS II (mean age 11.5 years, range 2-29 years) between the years 2005 and 2010. Passive ROM was measured by a goniometer, and height, by a stadiometer. Functional status was assessed by an age-appropriate health assessment questionnaire (HAQ).

RESULTS

(i) A strong correlation was observed between patients' age and Z-score of patients' height (R = 0.78, p < 0.001). (ii) A medium correlation was observed between Z-score of patients' height and passive shoulder flexion and abduction (R = 0.697, p < 0.001 and R = 0.63, p < 0.001, respectively). The progression of restriction was slower in attenuated patients. (iii) Restrictions in shoulder flexion and abduction were already observed before the second year of life. (iv) ROM limitations intensified and became more severe with age. (v) Activities of daily living depended on cognitive impairment of patients with MPS II.

CONCLUSION

Range of motion limitations in patients with MPS II correlate with patients' height, increase with patients' age and are more pronounced in a severe form of MPS II.

摘要

目的

本研究旨在评估黏多糖贮积症 II 型(MPS II)患者的肩部活动度(ROM),并将关节活动度与患者的身高、年龄和功能状态相关联。

方法

在 2005 年至 2010 年间,对 29 例 MPS II 患者(平均年龄 11.5 岁,范围 2-29 岁)进行了被动 ROM 和身高 Z 评分的随访。通过量角器测量被动 ROM,通过身高计测量身高。功能状态通过适合年龄的健康评估问卷(HAQ)进行评估。

结果

(i)患者年龄与患者身高 Z 评分之间存在很强的相关性(R = 0.78,p < 0.001)。(ii)患者身高 Z 评分与被动肩关节前屈和外展之间存在中度相关性(R = 0.697,p < 0.001 和 R = 0.63,p < 0.001)。衰减患者的限制进展较慢。(iii)在生命的第二年之前,已经观察到肩关节前屈和外展受限。(iv)ROM 限制随着年龄的增长而加剧且变得更加严重。(v)日常生活活动取决于 MPS II 患者的认知障碍。

结论

MPS II 患者的 ROM 限制与患者的身高相关,随患者年龄的增长而增加,在 MPS II 的严重形式中更为明显。

相似文献

1
Restricted joint range of motion in patients with MPS II: correlation with height, age and functional status.黏多糖贮积症 II 型患者的关节活动度受限:与身高、年龄和功能状态的相关性。
Acta Paediatr. 2012 Apr;101(4):e183-8. doi: 10.1111/j.1651-2227.2011.02522.x. Epub 2011 Dec 1.
2
Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients.重组人α-L-艾杜糖苷酸酶(拉罗尼酶)治疗黏多糖贮积症 I 型患者上肢活动受限的疗效。
J Inherit Metab Dis. 2010 Apr;33(2):151-7. doi: 10.1007/s10545-010-9059-9. Epub 2010 Mar 9.
3
Functional capacity evaluation of patients with mucopolysaccharidosis.黏多糖贮积症患者的功能能力评估
J Pediatr Rehabil Med. 2012;5(1):37-46. doi: 10.3233/PRM-2012-0194.
4
Efficacy of Enzyme Replacement Therapy on the range of motion of the upper and lower extremities in 16 Polish patients with mucopolysaccharidosis type II: A long-term follow-up study.十六例波兰黏多糖贮积症 II 型患者接受酶替代治疗对上下肢活动范围的疗效:一项长期随访研究。
Acta Biochim Pol. 2022 Feb 28;69(1):251-255. doi: 10.18388/abp.2020_6071.
5
Comparison of pediatric outcomes data collection instrument scores and range of motion before and after shoulder tendon transfers for children with brachial plexus birth palsy.臂丛神经产瘫患儿肩肌腱转移前后儿科结局数据收集工具评分及活动范围的比较
J Pediatr Orthop. 2008 Mar;28(2):259-64. doi: 10.1097/BPO.0b013e3181652135.
6
Assessment of shoulder range of motion: introduction of a novel patient self-assessment tool.肩部活动范围评估:一种新型患者自我评估工具的介绍
Arthroscopy. 2008 Jun;24(6):712-7. doi: 10.1016/j.arthro.2008.01.020. Epub 2008 Mar 21.
7
Effect of intervertebral disc height on postoperative motion and clinical outcomes after Prodisc-C cervical disc replacement.椎间盘高度对Prodisc-C颈椎间盘置换术后活动度及临床疗效的影响。
Spine J. 2009 Jul;9(7):551-5. doi: 10.1016/j.spinee.2009.03.008. Epub 2009 May 17.
8
Pediatric Escola Paulista de Medicina Range of Motion Scale: a reduced joint count scale for general use in juvenile rheumatoid arthritis.儿科圣保罗医学运动范围量表:一种简化关节计数量表,用于青少年类风湿关节炎的一般评估。
J Rheumatol. 1999 Apr;26(4):909-13.
9
Normal functional range of motion of the lumbar spine during 15 activities of daily living.腰椎在15项日常生活活动中的正常功能活动范围。
J Spinal Disord Tech. 2010 Apr;23(2):106-12. doi: 10.1097/BSD.0b013e3181981823.
10
Evaluation of ADL in patients with Hunter disease using FIM score.使用FIM评分评估亨廷顿病患者的日常生活活动能力。
Brain Dev. 2007 Jun;29(5):298-305. doi: 10.1016/j.braindev.2006.08.015. Epub 2007 Feb 20.

引用本文的文献

1
Unmet needs of adults living with mucopolysaccharidosis II: data from the Hunter Outcome Survey.黏多糖贮积症II型成年患者未满足的需求:来自亨特结果调查的数据。
Orphanet J Rare Dis. 2025 Jul 1;20(1):319. doi: 10.1186/s13023-024-03464-8.
2
Nebulized and intravenous enzyme replacement therapy in mice with mucopolysaccharidosis type II.雾化和静脉注射酶替代疗法治疗II型黏多糖贮积症小鼠
PLoS One. 2025 Jun 26;20(6):e0310485. doi: 10.1371/journal.pone.0310485. eCollection 2025.
3
Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland.
波兰黏多糖贮积症II型(亨特综合征)的诊断与管理
Biomedicines. 2023 Jun 8;11(6):1668. doi: 10.3390/biomedicines11061668.
4
Understanding the challenges, unmet needs, and expectations of mucopolysaccharidoses I, II and VI patients and their caregivers in France: a survey study.了解法国黏多糖贮积症 I、II 和 VI 患者及其照护者的挑战、未满足的需求和期望:一项调查研究。
Orphanet J Rare Dis. 2022 Dec 23;17(1):448. doi: 10.1186/s13023-022-02593-2.
5
Comparison of growth dynamics in different types of MPS: an attempt to explain the causes.不同类型 MPS 生长动态的比较:原因初探。
Orphanet J Rare Dis. 2022 Sep 5;17(1):339. doi: 10.1186/s13023-022-02486-4.
6
Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations.静脉内酶替代疗法治疗黏多糖贮积症:临床疗效和局限性。
Int J Mol Sci. 2020 Apr 23;21(8):2975. doi: 10.3390/ijms21082975.
7
Growth impairment and limited range of joint motion in children should raise suspicion of an attenuated form of mucopolysaccharidosis: expert opinion.儿童生长障碍和关节运动范围受限应引起对黏多糖贮积症衰减形式的怀疑:专家意见。
Eur J Pediatr. 2019 Apr;178(4):593-603. doi: 10.1007/s00431-019-03330-x. Epub 2019 Feb 11.
8
Quality of life in mucopolysaccharidoses: construction of a specific measure using the focus group technique.黏多糖贮积症患者的生活质量:运用焦点小组技术构建一项特定测评方法。
BMC Res Notes. 2018 Jan 15;11(1):28. doi: 10.1186/s13104-018-3157-4.
9
Birth weight in patients with mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS).II型黏多糖贮积症患者的出生体重:来自亨特结果调查(HOS)的数据。
Mol Genet Metab Rep. 2017 May 3;11:62-64. doi: 10.1016/j.ymgmr.2017.02.004. eCollection 2017 Jun.
10
Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues.黏多糖贮积症患者的健康相关生活质量:超越生物医学问题的探讨
Orphanet J Rare Dis. 2016 Aug 26;11(1):119. doi: 10.1186/s13023-016-0503-2.